loading

Finanzdaten der Xeris Biopharma Holdings Inc-Aktie (XERS)

Gewinn- und Verlustrechnung
Vierteljährlich
*Alle Zahlen in Millionen
Enddatum des Zeitraums 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31
Periodenlänge 3 Monate 3 Monate 3 Monate 3 Monate 3 Monate
Revenues
15.36%
85.81
74.38 71.54 60.12 60.10
Operating Expenses
2.05%
69.03
67.65 67.06 63.21 58.42
Benefits Costs and Expenses
291.29
- - - 260.17
Costs And Expenses
38.03%
93.38
67.65 67.06 63.21 81.88
Operating Income/Loss
149.19%
16.77
6.731 4.482 -3.09 1.679
Income/Loss From Continuing Operations Before Tax
376.26%
-205.48
74.38 -1.928 -9.22 -200.07
Income Tax Expense/Benefit, Deferred
-
- - - -
Income Tax Expense/Benefit
-
- - - -
Income/Loss From Continuing Operations After Tax
1,684%
11.08
0.621 -1.928 -9.22 -5.113
Net Income/Loss
1,684%
11.08
0.621 -1.928 -9.22 -5.113
Preferred Stock Dividends And Other Adjustments
-
- - - -
Attributable To Noncontrolling Interest
-
- - - -
Basic Average Shares
98.86%
1.8657
163.65 159.46 152.45 0.8106
Diluted Average Shares
92.01%
14.18
177.62 159.46 152.45 0.8106
Basic Earnings Per Share
0.07
- -0.01 -0.06 -0.03
Diluted Earnings Per Share
0.07
- -0.01 -0.06 -0.03
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic
-
- - - -
$46.06
price up icon 0.41%
$28.99
price up icon 1.33%
$54.07
price up icon 1.61%
$90.20
price up icon 0.16%
$141.15
price up icon 1.23%
biotechnology ONC
$288.30
price up icon 0.99%
Kapitalisierung:     |  Volumen (24h):